Credent Connect N Care Limited plans 26% Kartavya Healtheon stake
Key highlights
- Credent approved a proposed 26% Kartavya Healtheon stake on November 17, 2026.
- Credent has already acquired 6% of Kartavya Healtheon through a secondary purchase.
- Kartavya Healtheon reported FY 2025-26 revenue from operations of Rs 59.18 crore, versus Rs 52.05 crore in FY 2024-25.
- The transaction has an indicative completion period of within three months, with the share price to be set by a registered valuer.
powered by IRIS

Credent Connect N Care Limited approved a plan on November 17, 2026, to build a 26% stake in Kartavya Healtheon Private Limited, having already acquired 6% through a secondary purchase and proposing fresh equity subscription and conversion of an inter-corporate loan for the balance of the transaction structure.
Know Credent Connect N Care inside out
Results, valuation, peers and who's buying, in one view.
What has Credent approved for Kartavya Healtheon?
Credent approved a strategic investment intended to result in a 26% holding in Kartavya Healtheon on November 17, 2026. The board considered and approved the proposal at a meeting that began at 3:30 p.m. and concluded at 4:15 p.m., using secondary acquisition, subscription to newly issued equity and conversion of an outstanding inter-corporate loan into equity.
Credent said it had already acquired 6% of Kartavya Healtheon through a secondary share purchase. The company has not disclosed the number of shares represented by the completed 6% purchase or the proposed 26% holding, and it has not apportioned the balance of the proposed stake between the fresh equity subscription and loan-conversion routes.
Credent had informed the market on November 4, 2026, that it had granted an inter-corporate loan to Kartavya Healtheon. In its November 17 disclosure, Credent said it had granted the borrower an option or right to convert the outstanding loan, in whole or in part, into equity shares under the loan agreement and subject to applicable legal and regulatory requirements.
How will Credent complete the 26% Kartavya Healtheon stake?
Credent indicated that the proposed 26% stake should be completed within three months, through three mechanisms rather than only a secondary-market share purchase. The filing describes the consideration as cash consideration while also identifying subscription to fresh equity and conversion of the outstanding inter-corporate loan as components of the proposed shareholding structure.
The acquisition price has not been disclosed. Credent said the cost or price of the shares will be determined using a valuation report from a registered valuer, in accordance with the Companies Act, 2013, and other applicable laws and regulations; the filing therefore gives neither a total transaction value nor a per-share price.
No governmental or regulatory approvals are required for the acquisition, according to the November 17 filing. The board also authorised Tarun Sharma, Credent's chairman and managing director, to invest company funds as required, subject to board approval, although no funding amount was disclosed.
Got a follow-up? Ask IRIS
What does Kartavya Healtheon do and how has revenue changed?
Kartavya Healtheon provides integrated healthcare delivery services, including patient support and access programmes, corporate and occupational health, diagnostics support, wellness camps and specialty pharmacy. Its disclosed customers include pharmaceutical companies, corporates and healthcare providers, covering several healthcare-services segments rather than a single product line.
Kartavya Healtheon's revenue from operations rose to Rs 59.18 crore in FY 2025-26 from Rs 52.05 crore in FY 2024-25, an increase of Rs 7.13 crore. This followed an increase of Rs 28.01 crore from Rs 24.04 crore in FY 2023-24 to Rs 52.05 crore in FY 2024-25.
Kartavya Healtheon was incorporated on July 2, 2008, and its disclosed presence is in India. Its authorised share capital is Rs 45.3039 lakh and paid-up capital is Rs 29.0299 lakh, figures that are separate from the FY 2025-26 revenue of Rs 59.18 crore and do not establish the acquisition valuation.
Why is Credent investing in Kartavya Healtheon?
Credent said the strategic investment is intended to strengthen its presence in pharma patient-support and occupational-health services. It also cited potential synergies with its existing healthcare services, wellness, diagnostics and logistics businesses, while Kartavya Healtheon's operations include patient access programmes, diagnostics support, wellness camps and specialty pharmacy.
The stated rationale links Kartavya Healtheon's corporate and occupational-health services with Credent's occupational-health objective, and its patient support and access programmes with Credent's stated pharma patient-support objective. The November 17, 2026 filing does not quantify expected revenue synergies, cost savings, client additions or financial contribution from the proposed 26% stake.
The proposed transaction is not a related-party transaction, Credent said. It also stated that its promoter, promoter group and group companies have no interest in the acquisition, while the loan conversion remains subject to the November 4, 2026 loan agreement and applicable legal and regulatory requirements.
Conclusion
Credent's November 17, 2026 decision sets out a planned 26% strategic holding in Kartavya Healtheon, an India-based healthcare-services provider that reported FY 2025-26 revenue of Rs 59.18 crore. The structure combines a completed 6% secondary purchase with a proposed fresh equity subscription and possible conversion of an inter-corporate loan, rather than relying solely on a secondary cash acquisition.
The next disclosed milestones are completion within three months and determination of the share price by a registered valuer. Investors can also watch whether Credent converts all or part of its November 4, 2026 inter-corporate loan into Kartavya Healtheon equity and whether it discloses the transaction value or final ownership structure.


